Compositions for treatment of osteochondral disorders
AssigneeKatholieke Universiteit Leuven
InventorsVeerle Bloemen, Johanna Bolander, Frank Luyten
Life of this patent
Estimating the term…
Abstract
The application provides biocompatible carriers comprising bone forming and/or cartilage forming cells and methods for making them. The application further provides pharmaceutical compositions comprising said ATMPs and method of treatments using said ATMPs. The application further relates to said ATMPS for use in the treatment of bone disorders, cartilage disorders and joint disorders. The current invention further relates to method of treatments of bone disorders, cartilage disorders and joint disorders.
Claims20
A method for producing a cellular composition with in vivo bone forming potential, the method comprising the steps of:
- a. culturing periosteum derived mesenchymal stem cells in a serum-free medium, the serum-free medium being without a BMP (Bone Morphogenetic Protein) in that the serum-free medium does not contain an exogenous added BMP;
- b. culturing the periosteum derived mesenchymal stem cells obtained after step (a) in a serum-free medium in the presence of a BMP, thereby differentiating the periosteum derived mesenchymal stem cells into cells with an osteochondrogenic phenotype;
- and
- c. seeding and/or encapsulating the cells with an osteochondrogenic phenotype obtained after step (b) on or into a biocompatible carrier, wherein the serum-free medium in step (a) and step (b) each comprise two basal cell culture media in a ratio of about 1:1 (v/v), and comprise insulin, transferrin, selenium, α-ketoglutarate, ceruloplasmin, cholesterol, phosphatidyl ethanolamine, α-tochoferol acid succinate, reduced glutathione, taurine, and L-ascorbic acid 2-sulphate.
A method for producing a cellular composition with in vivo bone forming potential, the method comprising the steps of:
- a. culturing periosteum derived mesenchymal stem cells in a serum-free medium, the serum-free medium being without a BMP (Bone Morphogenetic Protein) in that the serum-free medium does not contain an exogenous added BMP;
- b. culturing the periosteum derived mesenchymal stem cells obtained after step (a) in a serum-free medium in the presence of a BMP, thereby differentiating the periosteum derived mesenchymal stem cells into cells with an osteochondrogenic phenotype;
- and
- c. seeding and/or encapsulating the cells with an osteochondrogenic phenotype obtained after step (b) on or into a biocompatible carrier.
Dependencies are inferred from the claim text.